SCHEMBL19781540

SCHEMBL19781540

CC(C)Oc1ccc(-c2cn3ccnc3cn2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.54
WDR5 P61964 1/20 0.41
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
NPC1 O15118 5/20 0.39
RAB9A P51151 5/20 0.39
PKM P14618 4/20 0.39
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
MAPK1 P28482 1/20 0.39
KDM4E B2RXH2 4/20 0.39
EPHX2 P34913 1/20 0.39
DYRK1A Q13627 2/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
GLA P06280 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
TGFBR1 P36897 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24460393 0.81 DYRK1A (0.59) CYP1A2WDR5DYRK1ATGFBR1GRM2
SCHEMBL10804911 0.80 CLK1 (0.47) CYP1A2WDR5TP53MAPTNPC1
SCHEMBL11140124 0.80 CYP1A2 (0.56) CYP1A2WDR5TP53MAPTNPC1
SCHEMBL20208560 0.78 KDM4E (0.55) CYP1A2MAPTNPC1RAB9AALDH1A1
SCHEMBL13336494 0.76 NPC1 (0.51) TP53NPC1RAB9AALDH1A1KDM4E
SCHEMBL24460392 0.76 RORC (0.41) CYP1A2WDR5TP53MAPTDYRK1A
SCHEMBL21644144 0.76 DYRK1A (0.59) CYP1A2MAPTDYRK1ATGFBR1FYN
SCHEMBL1542371 0.76 CHEK1 (0.49) TP53NPC1RAB9APKMALDH1A1
SCHEMBL16304078 0.75 KEAP1 (0.44) TP53MAPTNPC1RAB9APKM
SCHEMBL19781541 0.75 FYN (0.64) CYP1A2FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2022-09-08 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION C9, C1S, ZC3HAV1 CYP1A2 1811/4885WDR5 3258/4885TP53 3744/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S CYP1A2 1889/4885WDR5 3465/4885TP53 3381/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S CYP1A2 1889/4885WDR5 3465/4885TP53 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.